News Releases

November 16, 2022
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual Meeting Presented LAVA-051 clinical pharmacodynamic data demonstrating
» Full Release
November 3, 2022
LAVA Therapeutics to Present at the Jefferies London Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer,
» Full Release
November 3, 2022
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.  ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer,
» Full Release
November 1, 2022
LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of Fred
» Full Release
October 7, 2022
LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the Company will
» Full Release
September 26, 2022
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 ( Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors – – LAVA to Receive Upfront Payment of $50 Million, With Potential for Milestones of up to Approximately $650
» Full Release
September 13, 2022
LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Initial Phase 1/2a clinical findings for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients demonstrated encouraging anti-tumor activity and safety profile; on track to report additional clinical data in fourth quarter 2022 Enrollment continuing in LAVA-1207 Phase
» Full Release
September 7, 2022
LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer,
» Full Release
June 16, 2022
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients
Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at 2022 ASCO and EHA meetings UTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V.
» Full Release
June 15, 2022
LAVA Therapeutics Announces Two Appointments to its Board of Directors
James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies UTRECHT, The Netherlands and PHILADELPHIA, June 15, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on
» Full Release